- Opinion
- [Reporter's view]Was renewal of α-GPC right?
- by Lee, Tak-Sun Nov 14, 2019 03:27am
- The Ministry of Food and Drug Safety (MFDS) has virtually thrown out a re-evaluation card for choline alfoscerate formulations, which are the controversy of effectiveness in full swing. The MFDS instructed 130 pharmaceutical companies producing choline alfoscerate to submit safety and efficacy data by Nov 11th 2019. The re-evaluation of C
- Company
- Rolontis®to get ₩11.6 billion upon FDA's approval
- by An, Kyung-Jin Nov 14, 2019 03:25am
- The royalty scale of Rolontis® was first revealed. Hanmi Pharmaceuticals will receive rayalty of nearly &8361; 12 billion upon final FDA approval. After the release, Hanmi Pharmaceuticals will also likely receive a certain percentage of revenue annually, depending on sales. Spectrum Pharmaceuticals, Hanmi Pharmaceutical’s partner, recent
- Company
- Edarbi & Edarbyclor are going without a hitch
- by Eo, Yun-Ho Nov 14, 2019 03:23am
- Dong-A ST and Takeda Pharmaceutical Company Limited have settled down Edarbi and Edarbyclor prescribed in most general hospitals in Korea. According to the related industry, Edarbyclor combined with Azilsartan medoxomil and Chlorthalidone passed pharmacy and therapeutics committee review of over 30 medical institutions including SNUH, S
- Policy
- Ultomiris®, follow-up Soliris® to set with clinical trial
- by Lee, Tak-Sun Nov 14, 2019 03:21am
- Follow-up medicine after Soliris® which is a very expensive Orphan drug and &8361;40 billion sales in domestic market reached out the end of clinical trials. That’s what the medicine named Ultomiris®, and Phase III clinical trials was approved for PNH and Myasthenia gravis patients. There is high probability of becoming available in
- Company
- Kisqali joins reimbursement race as Faslodex combination
- by Eo, Yun-Ho Nov 13, 2019 01:11am
- A third CDK4/6 inhibitor in the Korean market, Kisqali now stands next to the first two drugs, Ibrance and Verzenio, as it applies for National Health Insurance (NHI) reimbursement listing. Novartis Korea recently submitted a reimbursement listing application of Kisqali (ribociclib) after its approval by Ministry of Food and Drug Safety
- Company
- Takeda provides free supply of MM treatment Ninlaro
- by Eo, Yun-Ho Nov 13, 2019 01:09am
- Takeda Pharmaceutical started providing free supply of oral multiple myeloma treatment, Ninlaro. According to industry insider, Takeda Pharmaceutical has decided to provide free supply the only oral option for multiple myeloma treatment, Ninlaro (ixazomib), last month and recently entered general hospital’s list of drug codes. Curre
- Opinion
- [Column] Imposing fine enough to prevent rebate?
- by Kim, Jung-Ju Nov 13, 2019 01:09am
- Korean government’s plan to revise illegal rebate penalty regulation and replace insurance reimbursement suspension with fine on an accused drug product came under fire. However, the government is committed to protect drug access considering patient’s safety and convenience. For the justification of rebate regulation against rebate,
- Company
- Doctors choose PPI to replace ranitidine alternative
- by Nho, Byung Chul Nov 12, 2019 06:26am
- Apparently, healthcare providers are in favor of proton pump inhibitor (PPI), as an alternative to ranitidine after confirmed contamination of carcinogen N-nitrosodimenthylamine (NDMA) in some of ranitidine products. Doctor Ville, an online community exclusive to healthcare providers, recently conducted a survey on 1,664 doctors about altern
- Company
- World's first Apixaban long-acting injection (LAI) by C-TRI
- by Lee, Seok-Jun Nov 11, 2019 10:41pm
- C-TRI acquired world patent for LAI containing anti-coagulant, apixaban. Apixaban is a mega drug with global sales of $9.9 billion last year. C-TRI announced on November 8 that it acquired a patent for a method for manufacturing LAI containing Apixaban using platform technology. It is a source technology for producing microspheres that
- Policy
- DREC passes Imfinzi, Liporaxel ‘conditional'
- by Kim, Jung-Ju Nov 11, 2019 10:41pm
- AstraZeneca’s immunotherapy Imfinzi (durvalumab) passed the first threshold to receive its insurance reimbursement in Korea. The treatment is soon to initiate its negotiation with National Health Insurance Service (NHIS) under the order of drug pricing negotiation by Ministry of Health and Welfare (MOHW). On the other hand, Daehwa
